http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 09:09:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html <p>TOKYO and CAMBRIDGE, Mass., Aug 27, 2026 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK(R))is now available in the U.S. for initiation therapy for early Alzheimer&apos;s disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD.</p><p>LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%28R%29+%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%26apos%3Bs+Disease/26989124.html Thu, 27 Aug 2026 09:09:00 -0400 4523 A.50216356 A.50217000 ESAIY ESALF O.05105698 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862 http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html <div class="xn-content"> <p class="prntac"><i>LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing </i><br /><i>for initiation and maintenance (approved in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>.)</i></p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location> and <location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4523" idsrc="xmltag.org" >Eisai Co., Ltd.</span> and <span value="NASDAQ-NMS:BIIB" idsrc="xmltag.org" >Biogen Inc.</span> (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) is now available in the <location value="LC/us" idsrc="xmltag.org" >U.S</location>. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to http://www.streetinsider.com/Press+Releases/LEQEMBI+IQLIK%C2%AE%28lecanemab-irmb%29+Autoinjector+for+Initiation+of+Therapy+Now+Available+in+the+U.S.+for+Early+Alzheimer%27s+Disease/26964425.html Mon, 24 Aug 2026 08:00:00 -0400 4523 4523 A.06822034 A.11820776 A.23703111 A.41824856 A.50207248 A.50216356 A.50217000 BIIB O.00070139 O.00093063 O.00386324 O.03211432 O.05105698 O.20026344 O.34598831 O.45181481 O.57063862